Health
27 Oct 2026
Merck’s drug cuts endometrial cancer death risk by 32%
The antibody‑drug conjugate sacituzumab tirumotecan, developed by Merck and Kelun‑Biotech, extended survival in patients with advanced endometrial cancer by almost seven months and lowered the chance of death by a third.
Read more